newsfilter
← Latest News
GlobeNewswire·

Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update

Received clearance to proceed with pivotal trial of amezalpat combination therapy for first-line hepatocellular carcinoma (HCC) in ChinaGranted orphan drug designation from the European Medicines Agency (EMA) for